Sarah Hamidi, M.D., FRCPC
Department of Endocrine Neoplasia and Hormonal Disorders, Division of Internal Medicine
Present Title & Affiliation
Primary Appointment
Associate Patient Safety Quality Officer, Department of Endocrine Neoplasia and HD, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas
Assistant Professor, Department of Endocrine Neoplasia and Hormonal Disorders, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas
Dual/Joint/Adjunct Appointment
Assistant Professor, Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 2017 | University of Montreal, Montreal, QC, CA, Medicinae Doctorem (M.D.) |
| 2013 | University of Montreal, Montreal, QC, CA, Pre-medical Year |
Postgraduate Training
| 2022-2024 | Advanced clinical and research fellowship, Oncologic Endocrinology, The University of Texas MD Anderson Cancer Center, Houston, TX |
| 2021-2022 | Chief Resident, Adult Endocrinology and Metabolism, The University of Montreal Hospital Center (CHUM), Montreal, QC |
| 2020-2022 | Clinical fellowship, Adult Endocrinology and Metabolism, University of Montreal, Montreal, QC |
| 2017-2020 | Clinical residency, Internal Medicine, University of Montreal, Montreal, QC |
Licenses & Certifications
| 2025 | Texas Medical License |
| 2025 | Texas Medical License |
| 2022 | Board Certification in Adult Endocrinology and Metabolism by the Royal College of Physicians and Surgeons of Canada |
| 2020 | Board Certification in Internal Medicine by the Royal College of Physicians and Surgeons of Canada |
Experience & Service
Faculty Academic Appointments
Attending Physician, The University of Montreal Hospital Center (CHUM), Montreal, QC, 2022 - 2022
Other Professional Positions
Clinical Research Scientist, Endocrinology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2024 - 2025
Intramural Institutional Committee Activities
Co-chair, ALTER ATC: Adaptive Learning to improve Thyroid Cancer Responses in Anaplastic Thyroid Cancer, The University of Texas MD Anderson Cancer Center, 2024 - Present
Member, ACTION QI: Advanced Cancers of the Thyroid early Interrogation for Oncologic and Neoadjuvant Targets, The University of Texas MD Anderson Cancer Center, 2023 - Present
Co-leader, Safety Monitoring for Patients with Advanced Thyroid Cancer on Targeted Therapy, The University of Texas MD Anderson Cancer Center, 2022 - Present
Extramural Institutional Committee Activities
Member, Adult Endocrinology and Metabolism Fellowship Program Admissions Committee, University of Montreal, 2021
Member, Continuing Professional Development Committee of Quebec's Association of Endocrinologists, Quebec's Association of Endocrinologists, 2021 - 2022
Co-chair, Continuing Professional Development Committee of the Division of Endocrinology and Metabolism, The University of Montreal Hospital Center (CHUM), 2021 - 2022
Member, Well-being Committee of the Division of Endocrinology and Metabolism, The University of Montreal Hospital Center, 2020 - 2022
Honors & Awards
| 2025 - Present | Travel Grant for the 2025 International Thyroid Congress American Thyroid Association, International Thyroid Congress American Thyroid Association |
| 2025 - Present | Cyrus Scholar Award for Outstanding Clinical Research Award, The University of Texas MD Anderson Cancer Center |
| 2024 | 2024 Outstanding Trainee Poster Award, American Thyroid Association |
| 2024 | Ridgeway Trainee Travel Grant, American Thyroid Association |
| 2023 | 2023 Women Advancing Thyroid Research Award, American Thyroid Association |
| 2023 | Ridgeway Trainee Travel Grant, American Thyroid Association |
| 2023 | First place at the 2023 Division of Internal Medicine Research Retreat, Clinical Research poster session, The University of Texas MD Anderson Cancer Center |
| 2022 | Dean's Honor List - Postgraduate Medical Education, University of Montreal |
| 2022 | The Department of Medicine's Trainee Excellence Award, The University of Montreal Hospital Center (CHUM) |
| 2018 | Internal Medicine Resident Excellence Award, Maisonneuve-Rosemont Hospital, Montreal, QC |
| 2017 | Dean's Honor List - M.D, University of Montreal |
| 2012 | Highest Honors and Jury's Praise at the French Baccalaureate, Stanislas College, Montreal, QC |
Professional Memberships
Selected Presentations & Talks
Local Presentations
- 2025. Basics of Clinical Research in Oncologic Endocrinology. Invited. Oncologic Endocrine Lecture Series. Houston, Texas, US.
- 2024. Can the Thyroid Differentiation Score Improve Characterization of Papillary Thyroid Cancers?. Invited. Endocrine Research Seminar Series. Houston, Texas, US.
- 2024. BRAF V600E-mutated Anaplastic Thyroid Cancer: Path to Cure ?. Invited. Division of Internal Medicine Research Grand Rounds. Houston, Texas, US.
- 2024. Circulating Tumor DNA for Disease Monitoring in Anaplastic Thyroid Cancer. Invited. ATC Research Retreat. Houston, Texas, US.
- 2024. Brain Metastases in Thyroid Cancer. Invited. Clinical Research Brain Metastases Providers' Meeting. Houston, Texas, US.
- 2023. Thyroid Cancer: an Overview. Invited. Experiential Training Program for Bayer. Houston, Texas, US.
- 2023. Safety Monitoring for Patients with Advanced Thyroid Cancer on Targeted Therapy. Invited. Internal Medicine and Cancer Survivorship Grand Rounds. Houston, Texas, US.
- 2023. Safety Monitoring for Patients with Advanced Thyroid Cancer on Targeted Therapy. Invited. Endocrine Patient Safety & Quality Meeting. Houston, Texas, US.
- 2023. Checkpoint Inhibition in Addition to Dabrafenib + Trametinib for BRAF V600E mutated Anaplastic Thyroid Cancer. Invited. Endocrine Research Seminar. Houston, Texas, US.
National Presentations
- 2025. Addition of VEGF or mTOR Inhibition to BRAF-targeted Therapy in BRAFV600E-Mutated ATC (BRAFm-ATC). Poster. Peer-reviewed conference presentation (Presenter). Scottsdale, Arizona, US.
- 2025. Management of Advanced Thyroid Cancers. Invited. Midwest Endocrinology Society 16th Annual Meeting. Minneapolis, US.
- 2025. Thyroid Cancer: An Overview. Invited. UPR/MDACC intensive course Advanced Topics in Cancer Research: Cancer Disparities, PR.
- 2024. Integrated Genomic Analysis Identifies Tumor Differentiation Status as a Crucial Determinant of Immune Infiltration and Potential Combinatorial Therapeutic Targets with Immunotherapy in Papillary Thyroid Carcinoma Patients. Conference. Chicago, IL, US.
- 2024. Characterization of RAS-mutant Anaplastic Thyroid Carcinoma. Poster. Chicago, IL, US.
- 2024. Clinicopathological Features of Advanced, RAS-driven Differentiated Thyroid Carcinoma. Poster. Chicago, IL, US.
- 2024. Efficacy and Safety of Selective RET Inhibitors in Hereditary Medullary Thyroid Carcinoma. Poster. Chicago, IL, US.
- 2024. Managing the Adverse Effects of Targeted Therapies for Advanced Thyroid Cancers. Invited. 27th International Thyroid Cancer Survivors' Conference. Houston, TX, US.
- 2024. Atezolizumab Plus Taxane Chemotherapy for the Treatment of Non-BRAF, Non-RAS Mutated Anaplastic Thyroid Carcinoma: Final Analysis. Poster. Chicago, IL, US.
- 2023. Efficacy of Adding Anti-PD1 Immunotherapy To Dabrafenib + Trametinib at Progression in BRAFV600E Mutated Anaplastic Thyroid Carcinoma. Poster. San Diego, CA, US.
- 2023. Emerging Treatments for Advanced Differentiated and Anaplastic Thyroid Cancers. Invited. 26th International Thyroid Cancer Survivors' Conference. Denver, CO, US.
- 2023. Emerging Treatments for Advanced Medullary Thyroid Cancer. Invited. 26th International Thyroid Cancer Survivors' Conference. Denver, CO, US.
- 2023. Checkpoint Inhibition in Addition to Dabrafenib + Trametinib for BRAF V600E-mutated Anaplastic Thyroid Cancer. Conference. Washington, D.C, US.
- 2022. Use of Thyroglobulin in the Follow-up of Low-Risk Differentiated Thyroid Cancers Treated Without Radioiodine Remnant Ablation. Poster. Montreal, QC, CA.
- 2022. Thyroid Paraganglioma, a Very Rare Condition: Case Report and Review of the Literature. Poster. Montreal, QC, CA.
- 2021. Real-life Experience with Lenvatinib Treatment of Advanced Thyroid Cancers from a Canadian Quaternary Care Center: Safety, Efficacy and Some Rare Side Effects. Poster. Virtual, US.
- 2021. Gastrointestinal Stromal Tumor Mimicking an Adrenal Incidentaloma: A Case Report. Poster. Virtual, US.
- 2019. Is There an Optimal Timing for Performing Post-Therapy Whole Body Scans After Radioiodine Treatment of Differentiated Thyroid Cancers?. Poster. Chicago, IL, US.
International Presentations
- 2025. The Genomic Landscape of Medullary Thyroid Carcinoma Identified by the Afirma RNA-Sequencing Classifier: Insights from a Large Real-World Cohort. Poster. 17th International Thyroid Conference (ITC). Rio de Janeiro, BR.
- 2025. Real-world Experience with Lenvatinib plus Pembrolizumab in Metastatic BRAF wild-type ATC. Invited. 17th International Thyroid Conference (ITC). Rio de Janeiro, BR.
- 2025. The Genomic Landscape of 250,000+ Thyroid Nodules Undergoing Exome-enriched RNA Sequencing. Invited. 17th International Thyroid Conference (ITC). Rio de Janeiro, BR.
- 2025. Comparison of Clinical Features and Outcomes Among Patients with MEN2A Syndrome and RET codon 634 Pathogenic Variants. Invited. 19th World MEN (Multiple Endocrine Neoplasia). Sao Paolo, BR.
- 2024. Efficacy of Adding Lenvatinib to BRAF-directed Therapy at Progression in BRAFV600E-mutated Anaplastic Thyroid Carcinoma. Poster. Athens, GR.
- 2023. Efficacy and Safety of Selective RET-inhibitors in Hereditary Medullary Thyroid Carcinoma: A Real-World Experience. Conference. Marseille, FR.
Formal Peers
- 2025. The Basics of Clinical research in Oncologic Endocrinology. Houston, Texas, US.
- 2025. Thyroid Cancer: An Overview. Puerto Rico, PR.
- 2024. Management of Anaplastic Thyroid Cancer in 2024. Houston, Texas, US.
- 2024. Current and Future Therapies for Advanced Thyroid Cancers. Houston, Texas, US.
Grant & Contract Support
| Date: | 2025 - Present |
| Title: | Neoadjuvant Treatment with Zanzalintinib for Advanced Thyroid Cancer |
| Funding Source: | The University of Texas MD Anderson Cancer Center |
| Role: | Co-PI |
| Date: | 2025 - Present |
| Title: | Identifying Biomarkers of Response to Radiation-Enhanced Checkpoint Blockade in non-BRAF mutated Anaplastic Thyroid Cancer |
| Funding Source: | U-Pilot Award by the U Foundation |
| Role: | Co-PI |
| Date: | 2024 - Present |
| Title: | Applying the Neoadjuvant Strategy to Non-BRAF Mutated Anaplastic Thyroid Carcinoma |
| Funding Source: | MD Anderson, Dept. of Head & Neck Surgery, ATC Multidisciplinary Petrick Research Program |
| Role: | Co-PI |
| Date: | 2024 |
| Title: | Association of the Thyroid Differentiation Score with Tumor Metabolism and Immune Phenotype |
| Funding Source: | Endocrine Fellows Foundation |
| Role: | Co-PI |
Selected Publications
Peer-Reviewed Articles
- Hamidi S, Bandi AV, Hamidi S, Iyer P, Busaidy NL, Cabanillas ME, Dadu R, Hu MI, Waguespack SG, Basmaci UN, Williams MD, Mansour M, Monroe MG, Gross ND, Goepfert RP, Perrier ND, Banuchi V, Wang JR, Maniakas A, Zafereo ME. Management of Retropharyngeal Lymph Node Metastases in Thyroid Cancer. Head and Neck Journal of the Sciences and Specialties of the Head and Neck, 2025. e-Pub 2025.
- Hawes EE, Banuchi VE, Maniakas A, Wang JR, Graham PH, Diersing JD, Busaidy NL, Cabanillas ME, Dadu R, Hamidi S, Iyer P, Waguespack SG, Ahmed S, Alizada S, Belcastro A, Alsharif R, Hu MI, Zafereo ME. Partial Laryngectomy for Thyroid Cancer: A Single Institution Case Series With Operative Techniques. Head Neck, 2025. e-Pub 2025. PMID: 40747656.
- Cabanillas, ME, Busaidy, NL, Gunn, GB, Iyer, PC, Ferrarotto, R, Gule-Monroe, MK, Maniakas, A, Williams, MD, Liu, S, Fellman, B, Spiotto, MT, Hamidi, S, Akhave, NS, Lee, A, Wang, RJ, De Sousa, LG, Marczyk, VR, Zafereo, M, Dadu, R. Adjuvant Pembrolizumab after Upfront Multimodal Therapy for Stage IVB Anaplastic Thyroid Cancer. Thyroid 35(7):763-770, 2025. e-Pub 2025. PMID: 40609521.
- Hamidi S, Maniakas A, Akhave NS, Banuchi VE, Busaidy NL, Dadu R, Ferrarotto R, Guise TA, Hofmann M, Hosseini S, Hu MI, Iyer PC, Mansour M, Marczyk VR, Roy-Chowdhuri S, Sherman SI, Sousa LG, Wang JR, Williams MD, Zafereo ME, Waguespack SG, Cabanillas ME. Characterization of Advanced RAS-driven Follicular-derived Thyroid Cancers and Review of Future Therapeutic Avenues. The Journal of Clinical Endocrinology & Metabolism, 2025. e-Pub 2025.
- Hamidi, S, Dadu, R, Iyer, PC, Busaidy, NL, Maniakas, A, Wang, RJ, Banuchi, VE, Hosseini, SM, Williams, MD, Zafereo, M, Cabanillas, ME. Circulating Tumor DNA as a Biomarker for Disease Surveillance in Anaplastic Thyroid Cancer. JCO Precision Oncology 9, 2025. e-Pub 2025. PMID: 40570261.
- Cabanillas, ME, Akhave, NS, Banuchi, VE, Busaidy, NL, Dadu, R, Ferrarotto, R, Gunn, GB, Hamidi, S, Hofmann, M, Hosseini, SM, Iyer, PC, Lai, SY, Lee, A, Maniakas, A, Ning, M, Spiotto, MT, Wang, RJ, Williams, MD, Zafereo, M. Reimagining the Therapeutic Approach for Anaplastic Thyroid Cancer. Thyroid 35(5):462-470, 2025. e-Pub 2025. PMID: 40388579.
- Marczyk, VR, Fazeli, S, Dadu, R, Busaidy, NL, Iyer, PC, Hu, MI, Sherman, SI, Hamidi, S, Hosseini, SM, Williams, MD, Ahmed, S, Routbort, MJ, Luthra, R, Roy Chowdhuri, S, San Lucas, FA, Patel, KP, Hong, DS, Zafereo, M, Wang, RJ, Maniakas, A, Waguespack, SG, Cabanillas, ME. NTRK Fusion-Positive Thyroid Carcinoma. JCO Precision Oncology 9, 2025. e-Pub 2025. PMID: 39983078.
- Hamidi S, Ning MS, Phan J, Zafereo ME, Gule-Monroe MK, Dadu R. Recurrent Poorly Differentiated Thyroid Cancer Successfully Treated With Radiation and Immunotherapy. JCEM Case Rep 3(2), 2025. e-Pub 2025.
- Dudzinski, SO, Cabanillas, ME, Hamidi, S, Marczyk, VR, Busaidy, NL, Dadu, R, Welsh, J, Hu, MI, Gunn, GB, Wang, C, Waguespack, SG, Phan, J, Beckham, TH, Chang, JY, Sherman, SI, Reddy, JP, Ying, AK, O'Reilly, M, Chen, A, Lee, A, Gandhi, S, Liao, Z, Ludmir, EB, Nguyen, Q, Lin, SH, Zafereo, M, Ning, M. Definitive Radiotherapy for Oligometastatic and Oligoprogressive Thyroid Cancer. JNCCN Journal of the National Comprehensive Cancer Network 23(1), 2025. e-Pub 2025. PMID: 39662038.
- Hamidi, S, Yedururi, S, Hu, MI, Busaidy, NL, Sherman, SI, Jimenez, C, Grubbs, EG, Maniakas, A, Zafereo, M, Subbiah, V, Waguespack, SG. Efficacy and Safety of Selective RET Inhibitors in Patients with Advanced Hereditary Medullary Thyroid Carcinoma. Thyroid 35(1):6-17, 2025. e-Pub 2025. PMID: 39630530.
- Hamidi S, Dadu R, Zafereo ME, Wang JR, Roy-Chowdhuri S, Williams MD, Hosseini S, Ferrarotto R, Akhave NS, Sousa LG, Iyer PC, Marczyk VR, Guise TA, Hofmann MC, Waguespack SG, Sherman SI, Hu MI, Busaidy NL, Maniakas A, Cabanillas ME. RAS-mutant follicular-derived advanced thyroid cancers: current knowledge and future avenues. e-Pub 2024.
- Hamidi S, Zafereo ME, Wang JR, Maniakas A, Busaidy NL, Dadu R, Iyer PC, Cabanillas ME. Circulating Tumor DNA as a Biomarker for Disease surveillance in Anaplastic Thyroid Cancer. JCO Precis Oncol. e-Pub 2024.
- Hamidi S, Mahvash A, Hu MI. Paraneoplastic Diarrhea From Medullary Thyroid Carcinoma Resolved With Yttrium-90 Radioembolization of Liver Metastases. JCEM Case Rep 2(8), 2024. e-Pub 2024. PMID: 39076377.
- Hamidi S, Iyer PC, Dadu R, Gule-Monroe MK, Maniakas A, Zafereo ME, Wang JR, Busaidy NL, Cabanillas ME. Checkpoint Inhibition in Addition to Dabrafenib/Trametinib for BRAFV600E-Mutated Anaplastic Thyroid Carcinoma. Thyroid 34(3):336-346, 2024. e-Pub 2024. PMID: 38226606.
- Hamidi S, Boucher A, Lemieux B, Rondeau G, Lebœuf R, Ste-Marie L, Le XK, Mircescu H. Lenvatinib Therapy for Advanced Thyroid Cancer: Real-Life Data on Safety, Efficacy, and Some Rare Side Effects. J Endocr Soc 6(6), 2022. e-Pub 2022. PMID: 35475024.
- Hamidi S, Mottard S, Berthiaume MJ, Doyon J, Bégin MJ, Bondaz L. Brown tumor of the iliac crest initially misdiagnosed as a giant cell tumor of the bone. Endocrinol Diabetes Metab Case Rep, 2020. e-Pub 2020. PMID: 32478667.
Invited Articles
- Shariq OA, Waguespack SG, Hamidi S, Kensing BC, Hu MI, Skefos CM, Perrier ND. Approach to the Patient: Hereditary Medullary Thyroid Carcinoma. J Clin Endocrinol Metab 110(9):2685-2697, 2025. e-Pub 2025. PMID: 40105880.
- Hamidi S, Maniakas A. Recent advances in anaplastic thyroid cancer management. Curr Opin Endocrinol Diabetes Obes 30(5):259-264, 2023. e-Pub 2023. PMID: 37410453.
Review Articles
- Hamidi, S, Maniakas, A, Cabanillas, ME. Advances in Anaplastic Thyroid Cancer Treatment. Endocrinology and Metabolism Clinics of North America 54(3):361-375, 2025. e-Pub 2025. PMID: 40716892.
- Hamidi S, Maniakas A, Cabanillas ME. Advances in Anaplastic Thyroid Cancer Treatment. Endocrinol Metab Clin North Am 54(3):361-375, 2025. e-Pub 2025. PMID: 40716892.
- Keam S, Turner N, Kugeratski FG, Rico R, Colunga-Minutti J, Poojary R, Alekseev S, Patel AB, Li YJ, Sheshadri A, Loghin ME, Woodman K, Aaroe AE, Hamidi S, Iyer PC, Palaskas NL, Wang Y, Nurieva R. Toxicity in the era of immune checkpoint inhibitor therapy. Front Immunol 15, 2024. e-Pub 2024.
- Hamidi S, Turner N, Ouni R, Rico R, Henderson YC, Puche M, Alekseev S, Colunga-Minutti JG, Zafereo ME, Lai SY, Kim ST, Cabanillas ME, Nurieva R. Emerging therapeutic options for follicular-derived thyroid cancer in the era of immunotherapy. Front Immunol 15, 2024. e-Pub 2024. PMID: 38868771.
- Hamidi S, Hu MI. RET kinase inhibitors for the treatment of RET-altered thyroid cancers: Current knowledge and future directions. Ann Endocrinol (Paris) 85(2):118-126, 2024. e-Pub 2024. PMID: 38342224.
- Keam, S, Turner, N, Grande Kugeratski, F, Rico, R, Colunga-Minutti, JG, Poojary, R, Alekseev, S, Patel, A, Li, YJ, Sheshadri, A, Loghin, ME, Woodman, K, Aaroe, AE, Hamidi, S, Iyer, PC, Palaskas, NL, Wang, Y, Nurieva, R. Toxicity in the era of immune checkpoint inhibitor therapy. Frontiers in immunology 15, 2024. e-Pub 2024. PMID: 39247203.
- Hamidi S, Hofmann M, Iyer PC, Cabanillas ME, Hu MI, Busaidy NL, Dadu R. Review article: new treatments for advanced differentiated thyroid cancers and potential mechanisms of drug resistance. Front Endocrinol (Lausanne) 14, 2023. e-Pub 2023. PMID: 37435488.
Other Articles
- Marczyk, VR, Fazeli, S, Dadu, R, Busaidy, NL, Iyer, PC, Hu, MI, Sherman, SI, Hamidi, S, Hosseini, SM, Williams, MD, Ahmed, S, Routbort, MJ, Luthra, R, Roy Chowdhuri, S, San Lucas, FA, Patel, KP, Hong, DS, Zafereo, M, Wang, RJ, Maniakas, A, Waguespack, SG, Cabanillas, ME Erratum. JCO Precision Oncology 9, 2025. PMID: 40632979.
- Hamidi S, Dadu R, Zafereo ME, Ferrarotto R, Wang JR, Maniakas A, Gunn G, Lee A, Spiotto MT, Iyer PC, Sousa LG, Akhave NS, Ahmed S, Learned KO, Lu C, Lai SY, Williams M, Hosseini S, Busaidy NL, Cabanillas ME Initial Management of BRAF V600E-Variant Anaplastic Thyroid Cancer: The FAST Multidisciplinary Group Consensus Statement. JAMA Oncol, 2024. PMID: 38990526.
Abstracts
- Marczyk VR, Hamidi S, Zafereo M, Waguespack SG, Dadu R, Busaidy NL, Iyer PC, Maniakas A, Banuchi V, Cabanillas ME, Wang JR. Characterization Of The Genomic Landscape Of BRAF-, RAS-, And Fusion-Negative Thyroid Carcinomas Underscores The Role Of Tumor Suppressor Genes Available. 17th International Thyroid Congress Scientific Program, 2025. e-Pub 2025.
- Hamidi S, Castellanos LE, Thosani S, Best CJ, Sherman SI, Dadu R, Brinkman AK, Khoja M, Hu MI, Waguespack SG, Weitzman SP. Real-Life Safety Monitoring for Patients with Advanced Thyroid Cancer on Targeted Therapy: A Quality Improvement Project. 2024 Annual Meeting of the Endocrine Society, 2025. e-Pub 2025.
- Iyer PC, Wang JR, Hamidi S, Busaidy NL, Ferrarotto R, Akhave NS, Sousa LG, Gunn GB, Spiotto MT, Huang Q, Cabanillas ME. GRASSROOT- Global Real-world data in patients with Advanced thyroid cancer on Standard of care and Specialized Interventions- Registry of Oncologic Outcomes with Testing and treatment. e-Pub 2024.
- Hamidi S, Wu C, Tarabichi M, Thennavan A, Jiang J, Han A, Erasmus L, Zhao X, Zafereo M, Henderson Y, Lai SY, Wang W, Cabanillas M, Wang JR. Integrated genomic analysis identifies tumor differentiation status as a critical determinant of immune infiltration and potential combinational therapeutic targets with immunotherapy for papillary thyroid carcinoma patients. 2024 American Thyroid Association Annual Meeting. e-Pub 2024.
- Houl JH, Mendez PM, Wang JR, Hamidi S, Maniakas A, Iyer PC, Lai SY, Cabanillas M, Busaidy NL, Dadu R, Zafereo M, Hofmann AM. Targeting the MAPK and DNA Repair Pathways in Poorly Differentiated and Anaplastic Thyroid Cancer Cells. 2024 American Thyroid Association Annual Meeting. e-Pub 2024.
- Abdallah D, Hamidi S, Dadu R, Busaidy NL, Iyer PC, Waguespack SG, Zafereo ME, Cabanillas ME. Fusion-Driven Anaplastic Thyroid Cancer (ATC): Characterization and Clinical Outcomes. 2024 American Thyroid Association Annual Meeting. e-Pub 2024.
- Marczyk VR, Hamidi S, Cabanillas ME. Identification of Somatic Events Associated with Anaplastic Transformation in BRAFV600E-driven Thyroid Carcinomas: NGS Profiling of 1,000 Thyroid Cancers. 2024 American Thyroid Association Annual Meeting. e-Pub 2024.
- Abubaker A, Henderson Y, Wang JR, Zafereo M, Banuchi V, Goswami M, Cabanillas ME, Busaidy N, Dadu R, Iyer P, Hamidi S, Williams M, Hosseini S, Lai SY, Maniakas A. Challenges and factors affecting successful patient-derived xenograft model establishment for anaplastic thyroid cancer. 2024 American Thyroid Association Annual Meeting. e-Pub 2024.
- Hamidi S, Dadu R, Ferrarotto R, Gule-Monroe M, Liu S, Fellman BM, Williams MD, Zafereo ME, Wang RJ, Lu C, Ning MS, McKinley B, Woodman SE, Duose DY, Gunn GB, Busaidy NL, Cabanillas ME. Cobimetinib plus atezolizumab for RAS and NF1/2-mutated poorly differentiated thyroid carcinoma. 2024 ASCO Annual Meeting 42(16-suppl), 2024. e-Pub 2024.
- Hamidi S, Dadu R, Ferrarotto R, Gule-Monroe M, Liu S, Fellman BM, Williams MD, Zafereo ME, Wang RJ, Lu C, Ning MS, McKinley B, Woodman SE, Duose DY, Gunn GB, Busaidy NL, E Cabanillas AM. Atezolizumab plus taxane chemotherapy for the treatment of non-BRAF, non-RAS mutated anaplastic thyroid carcinoma: Final analysis. 2024 ASCO Annual Meeting 42(16_suppl), 2024. e-Pub 2024.
- Cabanillas ME, Busaidy NL, Iyer PC, Gule-Monroe M, Gunn GB, Spiotto MT, Akhave N, Sousa L, Ferrarotto R, Zafereo ME, Wang RJ, Maniakas A, Liu S, Fellman B, Hamidi S, Dadu R. Adjuvant pembrolizumab (pembro) after multimodal therapy for anaplastic thyroid cancer (ATC). 2024 American Thyroid Association Annual Meeting, 2024. e-Pub 2024.
- Ramos HE, Hamidi S, Faria SC, Dadu R, Hu MI, Busaidy NL, Waguespack SG, Weitzman S, Sherman SI, Cabanillas ME. Redifferentiation therapy (RDT) in differentiated thyroid carcinomas (DTC): Real-World data of a large cohort of patients. 2024 American Thyroid Association Annual Meeting, 2024. e-Pub 2024.
- Cubb TD, Hamidi S, Gule-Monroe MK, Busaidy NL, Iyer PC, Shaw KR, Roy-Chowdhuri S, Sura GH, Zafereo ME, Wang JR, Banuchi VE, Maniakas A, Cabanillas ME. Effect of PI3K Pathway Activating Mutations (PI3Kpath-mutation) on Response to BRAF/MEK Inhibitor (BRAF/MEKi) Therapy in BRAFV600E Mutated Anaplastic Thyroid Cancer (BRAFV600Em-ATC), 2024. e-Pub 2024.
- Hamidi S, Iyer PC, Gule-Monroe MK, Maniakas A, Dadu R, Zafereo ME, Wang J, Busaidy NL, Cabanillas ME. Efficacy of adding anti-PD1 immunotherapy to dabrafenib + trametinib (DT) at progression in BRAFv600e mutated anaplastic thyroid carcinoma (BRAFm-ATC). Society for Immunotherapy of Cancer 38th Annual Meeting 11(Suppl 1):A514-A514, 2023. e-Pub 2023.
- Hamidi S, Iyer P, Gule‐Monroe M, Maniakas A, Dadu R, Zafereo M, Wang J, Busaidy N, Cabanillas M. Checkpoint Inhibition in Addition to Dabrafenib + Trametinib for BRAFV600E Mutated Anaplastic Thyroid Carcinoma. 2023 American Thyroid Association Annual Meeting 33(S1), 2023. e-Pub 2023.
- Ning M, Dudzinski S, Busaidy N, Dadu R, Welsh J, Hu M, Hamidi S, Marczyk VR, Gunn B, Wang C, Waguespack S, Phan J, Beckham T, Chang J, Sherman S, Reddy J, Ying A, O'Reilly M, Chen A, Lee A, Gandhi S, Liao Z, Ludmir E, Nguyen Q, Tang C, Lin S, Zafereo M, Cabanillas M. Definitive Radiotherapy for Oligometastatic and Oligoprogressive Differentiated Thyroid Carcinoma: A Potential Strategy to Defer Escalation of Systemic Therapy. 2023 American Thyroid Association Annual Meeting 33(S1), 2023. e-Pub 2023.
- Hamidi S, Bourdeau I, Boucher A, Mircescu H, Rondeau G, Leboeuf R. Thyroid Paraganglioma, a Very Rare Condition: Case Report and Review of the Literature. 2022 American Thyroid Association Annual Meeting 32(S1), 2022. e-Pub 2022.
- Hamidi S, Boucher A, Rondeau G, Leboeuf R, Mircescu H. Use of Thyroglobulin in the Follow-up of Low-Risk Differentiated Thyroid Cancers Treated Without Radioiodine Remnant Ablation. 2022 American Thyroid Association Annual Meeting 32(S1), 2022. e-Pub 2022.
- Hamidi S, Boucher A, Rondeau G, Lebœuf R, Lemieux B, Le XK, Mircescu H. Real-life Experience with Lenvatinib Treatment of Advanced Thyroid Cancers from a Canadian Quaternary Care Center: Safety, Efficacy and Some Rare Side Effects. 2021 American Thyroid Association Annual Meeting 31(S1), 2021. e-Pub 2021.
- Hamidi S, Mercier F, Bourdeau I, Rakel A. Gastrointestinal Stromal Tumor Mimicking an Adrenal Incidentaloma: A Case Report. The Endocrine Society Annual Meeting 2021 5(Supplement_1):A997, 2021. e-Pub 2021.
- Hamidi S, Mircescu H, Leboeuf R, Boucher A, Juneau D, Rondeau G. Optimal Timing for Performing Post-Therapy Whole Body Scans After Radioiodine Treatment of Differentiated Thyroid Cancers. 2019 American Thyroid Association Annual Meeting 29(s1), 2019. e-Pub 2019.
- Sarah Hamidi MD, Maria Cabanillas MD, Ramona Dadu MD, Mimi Hu MD, Steven Waguespack MD, Naifa Busaidy MD, MBBS PI, Melinda Vickers MS, Ann Uy RN, Sonal Gupta MD, Deyaa Adib MD, Maria Gule-Monroe MD, MD ChB SS. Safety and Efficacy of Second Dose of AIC100 CAR T-cell in Patients with Poorly Differentiated (PDTC) andAanaplastic Thyroid Carcinoma (ATC). 2025 American Thyroid Association Annual Meeting.
- Fournier I, Maniakas A, Wang JR, Banuchi V, Lai SY, Gule-Monroe MK, Ning MS, Williams MD, Li X, Dadu R, Busaidy NL, Iyer PC, Hamidi S, Cabanillas ME, Zafereo ME. Neoadjuvant BRAF/MEK inhibitor therapy and immunotherapy for BRAFV600E-mutated anaplastic thyroid cancers. . AHNS 2025 Annual Meeting.
- Ebrahimi S, Hamidi S, Baser HD, Ryoo Ali HJ, Koutroumpakis E, Kumar S, Cabanillas ME, Dadu R, Iyer PC, Hu MI, Busaidy NL, Waguespack SG, Mouhayar EN, Palaskas NL, Deswal A. Emergence of Hypertension in Thyroid Cancer Patients on BRAF ± MEK Inhibitors: A Closer Look at Incidence and Contributing Risk Factors. 2025 American Heart Association Annual Meeting.
- Hamidi S, Waguespack SG, Busaidy NL, Graham PH, Habra MA, Perrier ND, Sosa JA, Sherman SI, Skefos CB, Ying AK, Zafereo ME, Grubbs EG, Hu MI. Comparison of Clinical Features and Outcomes Among Patients with MEN 2A Syndrome and RET Codon 634 Pathogenic Variants. World MEN.
- Fournier I, Waguespack SG, Castellanos L, Iyer P, Hamidi S, Busaidy NL, Cabanillas ME, Dadu R, Hu MI, Williams MD, Palacios JA, Monroe MG, Banuchi VE, Wang JR, Maniakas A, Zafereo ME. Neoadjuvant Larotrectinib Before Surgery For NTRK Fusion-Positive Thyroid Cancer: A Case Series. 17th International Thyroid Congress Scientific Program.
- Fournier I, Jorge Eduardo AP, Mahmoud Innab MK, Zafereo ME, Wang JR, Gross ND, Lango MN, Goepfert RP, Sturgis EM, Grubbs EG, Graham PH, Gupta SK, Busaidy NL, Cabanillas ME, Dadu R, Hamidi S, Hu MI, Iyer P, Waguespack S, Ahmed S, Kwon M, Banuchi VE, Maniakas A, Hosseini SM, Williams MD. Prognostic Significance of BRAFV600E Status In Patients Diagnosed With Papillary Thyroid Cancer (PTC). 17th International Thyroid Congress Scientific Program.
- Marczyk VR, Wu CC, Hamidi S, Loberg MA, Thennavan A, Henderson Y, Sheng Q, Williams MD, Zafereo ME, Cabanillas ME, Lai SY, Huang E, Navin N, Weiss VL, Wang JR. A Tumor-Cell Specific Gene Signature Derived From Single-Cell Sequencing Is Prognostic Across Independent Cohorts Of Papillary Thyroid Carcinoma Patients. 17th International Thyroid Congress Scientific Program.
- Hamidi S, Waguespack SG, Wang JR, Weitzman SP, Zafereo ME, Busaidy NL, Dosiou C, Kuri DV, Chen Y, Hao Y, Alshalalfa M, Klopper JP, Hu MI. The Genomic Landscape oOf 250,000+ Thyroid Nodules Undergoing Exome-Enriched RNAna Sequencing. 17th International Thyroid Congress Scientific Program.
- Hamidi S, Vodopivec DM, Busaidy NL, Gule-Monroe MK, Akhave NS, Banuchi VE, Ferraroto R, Gunn G, Iyer PC, Lee A, Maniakas A, Ning MS, Sousa LG, Spiotto MT, Waguespack SG, Wang JR, Zafereo ME, Cabanillas ME, Dadu R. Real-World Experience With Lenatinib Plus Pembrolizumab In Metastatic BRAF Wild -Type Anaplastic Thyroid Carcinoma (BRAFWT-ATC). 17th International Thyroid Congress Scientific Program.
- Hamidi S, Waguespack SG, Wang JR, Zafereo ME, Grubbs EG, Salgado SA, Hoff AO, Gianoukakis AG, Chen Y, Hao Y, Alshalalfa M, Klopper JP, Hu MI. The Genomic Landscape Of Medullary Thyroid Carcinoma (MTC) Identified By The Afirma RNA-Sequencing Classifier: Insights From A Large Real-World Cohort. 17th International Thyroid Congress Scientific Program.
- Cubb T, Iyer P, Roecker Z, Sood A, Jazaeri A, Ramalingam P, Hamidi S, Dadu R, Ying A, Busaidy N, Waguespack S, Hu M, Sherman S, Cabanillas M. Malignant Struma Ovarii (MSO) Clinical Characteristics And Outcomes: A Retrospective Tertiary Cancer Center Experience. 17th International Thyroid Congress Scientific Program.
- Cabanillas ME, Busaidy NL, Iyer PC, Wang JR, Hu MI, Zafereo ME, Ferrarotto R, Lee A, Liu S, Gunn GB, Spiotto M, Hamidi S, Akhave N, de Sousa L, Maniakas A, Williams MD, Banuchi VE, Hosseini SM, Dadu R. Lenvatinib (LEN) plus Pembrolizumab (PEMBRO) in Anaplastic Thyroid Cancer (ATC): A Phase 2, Single Center Trial. 2025 American Thyroid Association Annual Meeting.
- Arpi Palacios JE, Fournier I, Maniakas A, Wang JR, Banuchi VE, Lango MN, Gule-Monroe MC, Williams MD, Mena M, Grubbs EG, Fisher SB, Xu L, Busaidy NL, Cabanillas ME, Castellanos LE, Dadu R, Hamidi S, Hu MI, Waguespack SG, Zafereo ME. Neoadjuvant Targeted Therapy for Locally Advanced Differentiated Thyroid Carcinoma. 2025 American Thyroid Association Annual Meeting.
- MBBS AA, Mouhammed Habra MD, MBBS PI, Sarah Hamidi MD. Emerging Mutations as Potential Therapeutic Targets in Advanced Thyroid Cancer with Brain Metastases: A Case Series. 2025 American Thyroid Association Annual Meeting.
- Ahmad Abubaker MD, Isabelle Fournier MD, Mark Zafereo MD, Jennifer R Wang MD, Victoria Banuchi MD, Elizabeth G Grubbs MD, Paul H Graham MD, Naifa L Busaidy MD, Maria E Cabanillas MD, Ramona Dadu MD, Sarah Hamidi MD, Mimi I Hu MD, Priyanka Iyer MD, Steven I Sherman MD, Steven G Waguespack MD, Sachin Kumar Gupta MS, Salmaan Ahmed MD, Michael Kwon MD, Michelle D Williams MD, S Mohsen Hosseini MD, Anastasios Maniakas MD. Surgical Management of Isthmus-confined Papillary Thyroid Carcinoma: A single Institution Retrospective Cohort Study. 2025 American Thyroid Association Annual Meeting.
- Zafereo ME, Cabanillas ME, Maniakas A, Wang JR, Chinn SB, Mady LJ, Fisher SB, Graham PH, Grubbs EG, Seim NB, Banuchi VE, Gule-Monroe MC, Williams MD, Xu L, Busaidy NL, Dadu R, Hamidi S, Iyer PC, Waguespack SG, Sherman SI, Nabhan FS, Ball DW, Worden FP, Hu MI. Neoadjuvant Treatment with Selpercatinib for RET-Altered Thyroid Cancer: A Multicenter Phase 2 Clinical Trial. 2025 American Thyroid Association Annual Meeting.
- Hamidi S, Busaidy NL, Iyer PC, Dadu R, Gule-Monroe R, Maniakas A, Wang JR, Banuchi V, Zafereo ME, Cabanillas ME. Addition of VEGF or mTOR Inhibition to BRAF-targeted Therapy in BRAFV600E-mutated ATC. 2025 American Thyroid Association Annual Meeting.
- Arpi Palacios JE, Hamidi S, Abubaker A, Cabanillas ME, Dadu R, Iyer PC, Busaidy NL, Zafereo ME, Wang JR, Banuchi VE, Gunn GB, Lee A, Ahmed S, Kwon M, Williams MD, Mansour M, Maniakas A. Clinicopathological Features of Papillary Thyroid Cancer (PTC)-to-Anaplastic Thyroid Carcinoma (ATC) Transformation. 2025 American Thyroid Association Annual Meeting.
- Hamidi S, Yedururi S, Hu MI, Busaidy NL, Sherman SI, Jimenez C, Grubbs EG, Maniakas A, Zafereo ME, Subbiah V, Waguespack SG. Efficacy and Safety of Selective RET Inhibitors in Hereditary Medullary Thyroid Carcinoma. 2024 American Thyroid Association Annual Meeting.
- Hamidi S, Maniakas A, Roy-Chowdhuri S, Hosseini S, Dadu R, Waguespack SG, Hu MI, Sherman SI, Iyer PC, Marczyk VR, Guise TA, Hofmann MC, Busaidy NL, Wang JR, Zafereo ME, Cabanillas ME. Clinicopathological Features of Advanced, RAS-driven Differentiated Thyroid Carcinoma. 2024 American Thyroid Association Annual Meeting.
- Castellanos LE, Hamidi S, Busaidy NL, Cabanillas ME, Dadu R, Hu MI, Iyer PC, Roy-Chowdhuri S, Sherman SI, Sura G, Wang JR, Williams MD, Iorgulescu JB, Waguespack SG. RAF Family Fusions in Thyroid Carcinomas: Clinicopathological Analysis of 16 Patients. 2024 American Thyroid Association Annual Meeting.
- Hamidi S, Dadu R, Zafereo ME, Wang JR, Roy-Chowdhuri S, Williams MD, Ferrarotto R, Akhave NS, Sousa LG, Iyer PC, Marczyk VR, Guise TA, Hofmann M, Busaidy NL, Maniakas A, Cabanillas ME. Characterization of RAS-mutant Anaplastic Thyroid Carcinoma. 2024 American Thyroid Association Annual Meeting.
- Ning MS, Dudzinski SO, Busaidy NL, Dadu R, Hamidi S, Welsh J, Gunn B, Waguespack SG, Hu MI, Marczyk VR, Spiotto M, Phan J, Reddy JP, Lee A, Ludmir EB, Maniakas A, Iyer P, Beckham T, Zafereo MA, E Cabanillas AM. Consolidative radiotherapy for oligometastatic and oligoprogressive anaplastic thyroid carcinoma: the potential utility of local therapy for limited distant sites. 2024 American Thyroid Association Annual Meeting.
- Houl JH, Yarmand R, Mendez PM, Henderson Y, Wang JR, Hamidi S, Maniakas A, Iyer PC, Lai SY, Cabanillas M, Busaidy NL, Dadu R, Zafereo M, Hofmann AM. Role of ETV5/p38 signaling Axis in BRAF-Mutated. 2024 American Thyroid Association Annual Meeting.
Letters to the Editor
- Matrone A, Kroiss M, Gild ML, Hamidi S, Sayehli CM, Siddal R, Gambale C, Prete A, Hu MI, Robinson BG, Elisei R. Erectile Dysfunction in Patients Treated with Selpercatinib for RET-Altered Thyroid Cancer. Thyroid, 2024.
Patient Reviews
CV information above last modified October 29, 2025